Overview

The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients

Status:
Recruiting

Trial end date:
2021-12-01

Target enrollment:
0

Participant gender:
All

Summary

The study is to evaluate the effect of Mycophenolate Mofetil compared with losartan alone on time to doubling of serum creatinine or the onset of end stage renal disease in patients with advanced IgA nephropathy who are treated with the maximal tolerated daily dose of losartan.The study will also assess the effects of MMF compared with losartan alone on the changes of urine albumin excretion and the changes in estimated glomerular filtration rate.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Fan Fan Hou

Treatments:

Losartan
Mycophenolate mofetil
Mycophenolic Acid

Criteria

Inclusion Criteria:

- Biopsy-proven primary IgA nephropathy with urinary proteinuria excretion over 1g/24
hour,subjects must meet 2 of the following criteria:

1. global glomerular sclerosis plus focal segmental glomerular sclerosis ratio ≥50%

2. eGFR 30 to 60 ml/min

3. Hypertension (blood pressure over 140/90 mmHg or taking antihypertensive drugs)

Exclusion Criteria:

1. Secondary IgA nephropathy

2. Familial IgA nephropathy

3. Concomitant disease: cancer, infection, diabetes mellitus, connective tissue disease,
abnormal liver function

4. Pregnancy or breasting

5. Inability to comply with study and follow-up procedures